238 related articles for article (PubMed ID: 579346)
21. Comparative microscopic study of cardiotoxicity and skin toxicity of anthracycline analogs.
Dantchev D; Balercia G; Bourut C; Anjo A; Maral R; Mathé G
Biomed Pharmacother; 1984; 38(7):322-8. PubMed ID: 6240996
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines.
Penco S; Casazza AM; Franchi G; Barbieri B; Bellini O; Podestà A; Savi G; Pratesi G; Geroni C; Di Marco A; Arcamone F
Cancer Treat Rep; 1983; 67(7-8):665-73. PubMed ID: 6575865
[TBL] [Abstract][Full Text] [Related]
23. [Production conditions and properties of the new antineoplastic antibiotic No. 294].
Brazhnikova MG; Kudinova MK; Vishniakova IA; Gauze GF; Preobrazhenskaia TP
Antibiotiki; 1970 Aug; 15(8):675-8. PubMed ID: 5537044
[No Abstract] [Full Text] [Related]
24. Mutagenicity of aclacinomycin A and daunomycin derivatives.
Umezawa K; Sawamura M; Matsushima T; Sugimura T
Cancer Res; 1978 Jun; 38(6):1782-4. PubMed ID: 348304
[TBL] [Abstract][Full Text] [Related]
25. Aclacinomycin X, a novel anthracycline antibiotic produced by Streptomyces galilaeus ATCC 31133.
Kim HS; Kim YH; Yoo OJ; Lee JJ
Biosci Biotechnol Biochem; 1996 May; 60(5):906-8. PubMed ID: 8704322
[TBL] [Abstract][Full Text] [Related]
26. Oncostatic effects of Alangium vitiense extracts (ICIG-EORTC 1131, 1186 and 1207) on lymphoid murine tumors.
Mathé G; Hayat M; Chenu E; Husson HP; Thevenet T; Kan C; Potier P
Cancer Res; 1978 May; 38(5):1465-7. PubMed ID: 580415
[TBL] [Abstract][Full Text] [Related]
27. Induction of chromosomal aberrations by the anthracycline antitumor antibiotics N,N-dimethyldaunomycin and aclacinomycin A.
Steinheider G; Westendorf J; Marquardt H
Experientia; 1987 May; 43(5):586-8. PubMed ID: 3472901
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of the antitumor activity of adriamycin by Tween 80.
Casazza AM; Pratesi G; Giuliani F; Formelli F; Di Marco A
Tumori; 1978 Apr; 64(2):115-29. PubMed ID: 675847
[TBL] [Abstract][Full Text] [Related]
29. [Antineoplastic effect of antibiotics 3002 and 3853].
Rossolimo OK; Maksimova TS; Sveshnikova MA; Ol'khovatova OL; Kovsharova IN
Antibiotiki; 1971; 16(4):320-2. PubMed ID: 5109579
[No Abstract] [Full Text] [Related]
30. Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A.
Rose WC; Schurig JE; Huftalen JB; Bradner WT
Cancer Res; 1983 Apr; 43(4):1504-10. PubMed ID: 6831399
[No Abstract] [Full Text] [Related]
31. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
32. Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D.
Wilkoff LJ; Dulmadge EA
J Natl Cancer Inst; 1978 Dec; 61(6):1521-4. PubMed ID: 281559
[TBL] [Abstract][Full Text] [Related]
33. Antitumor anthracycline antibiotics, aclacinomycin A and analogues. I. Taxonomy, production, isolation and physicochemical properties.
Oki T; Kitamura I; Yoshimoto A; Matsuzawa Y; Shibamoto N; Ogasawara T; Inui T; Takamatsu A; Takeuchi T; Masuda T; Hamada M; Suda H; Ishizuka M; Sawa T; Umezawa H
J Antibiot (Tokyo); 1979 Aug; 32(8):791-800. PubMed ID: 500500
[TBL] [Abstract][Full Text] [Related]
34. New anthracycline metabolites from mutant strains of Streptomyces galilaeus MA144-M1. I. Isolation and characterization of various blocked mutants.
Yoshimoto A; Matsuzawa Y; Oki T; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1981 Aug; 34(8):951-8. PubMed ID: 6947976
[TBL] [Abstract][Full Text] [Related]
35. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
[TBL] [Abstract][Full Text] [Related]
36. [Antitumor activity of the components of a carminomycin complex].
Shorin VA; Bazhanov VS; Averbukh LA
Antibiotiki; 1977 Jan; 22(1):69-74. PubMed ID: 576573
[TBL] [Abstract][Full Text] [Related]
37. Cellular accumulation and disposition of aclacinomycin A.
Egorin MJ; Clawson RE; Ross LA; Schlossberger NM; Bachur NR
Cancer Res; 1979 Nov; 39(11):4396-400. PubMed ID: 498071
[TBL] [Abstract][Full Text] [Related]
38. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
39. [Cardiotoxic study of aclacinomycin A. Subacute cardiotoxicity of aclacinomycin A and its recovery in hamsters (author's transl)].
Hirano S; Tone H; Sunaga T
Jpn J Antibiot; 1980 Mar; 33(3):268-80. PubMed ID: 6931237
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
